Information in Investor's Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or perfo ...

Core Insights - Emory University Hospital has become the first hospital to adopt the LIBERTY Endovascular Robotic System, aligning with its commitment to advancing interventional radiology [1][5] - LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, designed to enhance precision and reduce radiation exposure [2][6] - Microbot Medical is collaborating with Emory to establish an Endovascular Robotics Program, aiming to improve patient care in various peripheral intervention procedures [1][3] Company Overview - Microbot Medical Inc. is focused on transforming endovascular procedures through advanced robotic technology, with LIBERTY being the first FDA-cleared single-use robotic solution [6] - The company emphasizes innovation and has a strong intellectual property portfolio, positioning itself as a leader in the future of endovascular care [6] Market Strategy - The limited market release of LIBERTY has commenced, with plans for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026 [2] - The adoption of LIBERTY is seen as a significant milestone in the surgical robotic space, reflecting years of dedication and progress by the Microbot team [5]